Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Italy / NCT05880407
Recruiting Not applicable

Pilot Study of Percutaneous Correction of Hallux Valgus

NCT05880407 · tracked via the Priya Life Science Italy tracker
Sponsor
Istituto Ortopedico Rizzoli
Phase
Not applicable
Started
2022-02-22
Last updated
2026-05-04

Condition(s) studied

Hallux Valgus

Investigational drug(s) / intervention(s)

SERI osteotomypercutaneous osteotomy according to Chevron

SERI osteotomy: Correction of varus deformity of the 1st Metatarsal that is stabilized with Kirschnner wire

percutaneous osteotomy according to Chevron: Correction of varus deformity by osteotomy stabilization with 2 screws inserted via dorsal percutaneous accesses to the 1st Metatarsal.

Study summary

This is a pilot study with a randomized controlled design.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * Patients of both sexes with adult hallux valgus with indication for corrective surgical treatment * HVA (hallux valgus angle): 20°-40° * IMA (intermetatarsal angle): 10°-20° Exclusion Criteria: * Patients with instability of the first metatarsophalangeal joint * Patients with severe morphostructural alterations or other pathologies in the foot and lower limb * patients requiring additional surgical procedures * patients with severe vascular and neurological systemic pathologies * systemic pathologies that may impair bone consolidation

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Istituto Ortopedico Rizzoli Bologna Italy Recruiting

More Istituto Ortopedico Rizzoli trials in Italy

Assessment of Periprosthetic Bone Mineral Density in Patients Undergoing Total Knee Prosthesis of Different Design Recruiting
Comparison Between the Use of the Tensioner and Standard Surgical Technique for Ligament Balancing of Total Knee Prostheses Recruiting
Functional and Morphological Characterization of Multiple Osteochondromas Disorder Recruiting
Active Informed Consent: a New Solution to Improve and Objectively Test the Patient Understanding of Complex Surgical Procedures Proposals Recruiting
Evaluation of Clinical-functional and Radiographic Outcomes in Patients Who Underwent Meniscal Allograft Transplantation (MAT) at 10 Years. Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05880407 on ClinicalTrials.gov ↗ ← All trials in Italy